Myxoid stroma is associated with postoperative relapse in patients with stage II colon cancer

Abstract Background: Fibrosis surrounding cancer cells has been shown to affect cancer cell metastatic behavior. The present study aimed to explore the utility of myxoid stroma as a predictive factor for postoperative relapse in patients with stage II colon cancer.Methods: The present study retrospectively investigated 169 patients who underwent curative surgical resection of stage II colon cancer. The fibrotic stroma was classified according to Ueno’s criteria, and the patients were divided into the myxoid (MY) group and the non-MY (NMY) group. We also recorded tumor budding (TB) and investigated the combination of MY and TB for postoperative relapse. Postoperative survival was also explored.Results: Thirty-two (18.9%) patients had MY. MY was significantly associated with tumor budding (TB) and postoperative relapse (p<0.001 and p<0.001, respectively). The 5-year RFS rates in MY group and NMY group were 52.1% and 94.6% (p<0.0001), and the 5-year OS rates in MY group and NMY group were 74.6% and 93.3% (p=0.001). Multivariate analysis showed that both MY and TB were significant risk factors for postoperative relapse (p<0.001 and p=0.02, respectively), and that only TB was a significant risk factor for OS (p=0.043). Furthermore, compared with patients with either one of MY or TB, patients with both MY and TB had postoperative relapse more frequently (11.4% vs. 53.8%).Conclusions: The present study suggests that MY is a predictive marker for postoperative relapse in patients with stage II colon cancer.

Download Full-text

Myxoid stroma is associated with postoperative relapse in patients with stage II colon cancer

10.21203/rs.2.20269/v1 ◽

2020 ◽

Author(s):

Takashi Okuyama ◽

Shinichi Sameshima ◽

Emiko Takeshita ◽

Takashi Mitsui ◽

Takuji Noro ◽

...

Keyword(s):

Risk Factors ◽

Colon Cancer ◽

Survival Rates ◽

Significant Risk ◽

Predictive Marker ◽

Stage Ii ◽

Myxoid Stroma ◽

Metastatic Behavior ◽

Stage Ii Colon Cancer ◽

Overall Survival Rates

Abstract Background Fibrosis surrounding cancer cells has been shown to affect cancer cell metastatic behavior. The present study aimed to explore the utility of myxoid stroma as a predictive factor for postoperative relapse in colon cancer patients. Methods The present study retrospectively investigated 169 patients who underwent curative surgical resection of stage II colon cancer. The fibrotic stroma was classified according to Ueno’s criteria, and the patients were divided into the myxoid (MY) group and the non-MY (NMY) group. Results Thirty-two (18.9%) patients had MY. MY was significantly associated with tumor budding (TB) and postoperative relapse (p<0.001 and p<0.001, respectively). Five-year relapse-free and overall survival rates were 52.1% and 94.6%, respectively, in the MY group and 74.6% and 93.3%, respectively, in the NMY group (p<0.001 and p=0.001, respectively). Multivariate analysis showed that both MY and TB were significant risk factors for postoperative relapse (; p<0.001, and p=0.02, respectively). Furthermore, compared with patients with either one of MY or TB, patients with both MY and TB had postoperative relapse significantly more frequently (11.4% vs. 53.8%). Conclusions The present study suggests that MY is a predictive marker for postoperative relapse in patients with stage II colon cancer.

Download Full-text

Myxoid stroma is associated with postoperative relapse in patients with stage II colon cancer

10.21203/rs.2.20269/v2 ◽

2020 ◽

Author(s):

Takashi Okuyama ◽

Shinichi Sameshima ◽

Emiko Takeshita ◽

Takashi Mitsui ◽

Takuji Noro ◽

...

Keyword(s):

Risk Factors ◽

Colon Cancer ◽

Multivariate Analysis ◽

Significant Risk ◽

Predictive Marker ◽

Stage Ii ◽

Tumor Budding ◽

Myxoid Stroma ◽

Metastatic Behavior ◽

Stage Ii Colon Cancer

Abstract Background: Fibrosis surrounding cancer cells has been shown to affect cancer cell metastatic behavior. The present study aimed to explore the utility of myxoid stroma as a predictive factor for postoperative relapse in patients with stage II colon cancer.Methods: The present study retrospectively investigated 169 patients who underwent curative surgical resection of stage II colon cancer. The fibrotic stroma was classified according to Ueno’s criteria, and the patients were divided into the myxoid (MY) group and the non-MY (NMY) group. We also recorded tumor budding (TB) and investigated the combination of MY and TB for postoperative relapse. Postoperative survival was also explored.Results: Thirty-two (18.9%) patients had MY. MY was significantly associated with tumor budding (TB) and postoperative relapse (p<0.001 and p<0.001, respectively). The 5-year RFS rates in MY group and NMY group were 52.1% and 94.6% (p<0.0001), and the 5-year OS rates in MY group and NMY group were 74.6% and 93.3% (p=0.001). Multivariate analysis showed that both MY and TB were significant risk factors for postoperative relapse (; p<0.001, and p=0.02, respectively). Furthermore, compared with patients with either one of MY or TB, patients with both MY and TB had postoperative relapse significantly more frequently (11.4% vs. 53.8%).Conclusions: The present study suggests that MY is a predictive marker for postoperative relapse in patients with stage II colon cancer.

Download Full-text

American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer

Yearbook of Oncology ◽

10.1016/s1040-1741(08)70196-9 ◽

2006 ◽

Vol 2006 ◽

pp. 285-286

Author(s):

P.J. Loehrer

Keyword(s):

Colon Cancer ◽

Adjuvant Chemotherapy ◽

Clinical Oncology ◽

Stage Ii ◽

American Society ◽

Stage Ii Colon Cancer

Download Full-text

CDX2 and Muc2 immunohistochemistry as prognostic markers in stage II colon cancer

Human Pathology ◽

10.1016/j.humpath.2019.05.005 ◽

2019 ◽

Vol 90 ◽

pp. 70-79

Author(s):

Matthew J. Cecchini ◽

Joanna C. Walsh ◽

Jeremy Parfitt ◽

Subrata Chakrabarti ◽

Rohann J. Correa ◽

...

Keyword(s):

Colon Cancer ◽

Prognostic Markers ◽

Stage Ii ◽

Stage Ii Colon Cancer

Download Full-text

Association of chemotherapy with survival in stage II colon cancer patients who received radical surgery: a retrospective cohort study

BMC Cancer ◽

10.1186/s12885-021-08057-3 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Zhihao Lv ◽

Yuqi Liang ◽

Huaxi Liu ◽

Delong Mo

Keyword(s):

Colon Cancer ◽

Overall Survival ◽

Cancer Patients ◽

Prediction Models ◽

Radical Surgery ◽

Survival Rates ◽

Stage Ii ◽

Survival Prediction ◽

Stage Ii Colon Cancer ◽

Overall Survival Rates

Abstract Background It remains controversial whether patients with Stage II colon cancer would benefit from chemotherapy after radical surgery. This study aims to assess the real effectiveness of chemotherapy in patients with stage II colon cancer undergoing radical surgery and to construct survival prediction models to predict the survival benefits of chemotherapy. Methods Data for stage II colon cancer patients with radical surgery were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching (1:1) was performed according to receive or not receive chemotherapy. Competitive risk regression models were used to assess colon cancer cause-specific death (CSD) and non-colon cancer cause-specific death (NCSD). Survival prediction nomograms were constructed to predict overall survival (OS) and colon cancer cause-specific survival (CSS). The predictive abilities of the constructed models were evaluated by the concordance indexes (C-indexes) and calibration curves. Results A total of 25,110 patients were identified, 21.7% received chemotherapy, and 78.3% were without chemotherapy. A total of 10,916 patients were extracted after propensity score matching. The estimated 3-year overall survival rates of chemotherapy were 0.7% higher than non- chemotherapy. The estimated 5-year and 10-year overall survival rates of non-chemotherapy were 1.3 and 2.1% higher than chemotherapy, respectively. Survival prediction models showed good discrimination (the C-indexes between 0.582 and 0.757) and excellent calibration. Conclusions Chemotherapy improves the short-term (43 months) survival benefit of stage II colon cancer patients who received radical surgery. Survival prediction models can be used to predict OS and CSS of patients receiving chemotherapy as well as OS and CSS of patients not receiving chemotherapy and to make individualized treatment recommendations for stage II colon cancer patients who received radical surgery.

Download Full-text